The clinical therapeutic effect of matrine and lamivudine on the active cirrhosis

Objective To investigate the clinical therapeutic effect of matrine and lamivudine on the active hepatocirrhosis. Methods Sixty three patients with active hepatocirrhosis received matrine and lamivudine(matrine 200mg daily for 8 weeks, lamivudine 100 mg Daily for 1 year). The liver function, the values of serum liver fibrosis including hyaluronia acid (HA), laminin (LN), procollagen type III(PC III), procollagen type IV(IV C) before and after matrine and lamivudine administration were compared. HBV-DNA at 1, 3, 6, 12 months after matrine and lamivudine treatment were detected. Results The value of ALT, AST of treatment group was decreased comparing the control groups, the value of serum liver fibrosis markers were decreased after treatment. Differences between therapy group and control group were obvious (P0. 01). The value of HBV-DNA was decreased in treatment comparing the control group. Conclusion Matrine and lamivudine showed an obvious effect on the treatment of active hepatocirrhosis.